Topic resource collection
Approved comparison material connected to this topic.
6 resourcesRead both sides
PT-141 (Bremelanotide) Melanocortin receptor agonist in hypothalamus. Increases dopaminergic arousal signalling MC3/MC4 receptors in medial preoptic area FDA-approved for HSDD in premenopausal women (RECONNECT trial, n=1,267) Mos…
Before adopting any peptide protocol, clinicians need to understand which compounds have randomised controlled trial evidence versus case series or mechanistic studies only. The table below compares the four most commonly referen…
GHK-Cu Copper chelation, MMP modulation, collagen remodeling Topical 2–3mg/mL twice daily 12% increase in follicle density, 18% increase in shaft diameter (24 weeks, Dermatologic Therapy 2023) Best for localized androgenetic alop…
Bremelanotide (PT-141) MC3R/MC4R agonist. Increases hypothalamic dopamine and arousal signaling Subcutaneous injection (1.75mg) FDA-approved for HSDD; Phase 3 RCT data 40% experience nausea in first 2 doses; requires 45-min pre-a…
PT-141 (Bremelanotide) Melanocortin-4 receptor agonist Hypothalamus (dopamine pathways) 45–60 minutes subcutaneous FDA-approved; Phase 3 RCTs in 1,267 women Strongest evidence for generalized low libido in premenopausal women; wo…
Follistatin Binds activin to enhance FSH receptor sensitivity in granulosa cells Diminished ovarian reserve, poor responder protocols 1–3 mg/kg subcutaneously during early follicular phase Subcutaneous injection Promising for DOR…